CN1263510C - 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用 - Google Patents

多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用 Download PDF

Info

Publication number
CN1263510C
CN1263510C CNB998121703A CN99812170A CN1263510C CN 1263510 C CN1263510 C CN 1263510C CN B998121703 A CNB998121703 A CN B998121703A CN 99812170 A CN99812170 A CN 99812170A CN 1263510 C CN1263510 C CN 1263510C
Authority
CN
China
Prior art keywords
polysaccharide
oligosaccharide
conjugate
group
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998121703A
Other languages
English (en)
Chinese (zh)
Other versions
CN1323221A (zh
Inventor
F·米绍
C·－H·黄
C·乌伊茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter Biotech Technology SARL
Original Assignee
Baxter Healthcare SA
Baxter Biotech Technology SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter Biotech Technology SARL filed Critical Baxter Healthcare SA
Publication of CN1323221A publication Critical patent/CN1323221A/zh
Application granted granted Critical
Publication of CN1263510C publication Critical patent/CN1263510C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB998121703A 1998-08-19 1999-08-18 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用 Expired - Fee Related CN1263510C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9712098P 1998-08-19 1998-08-19
US60/097,120 1998-08-19
US37691199A 1999-08-18 1999-08-18
US09/376,911 1999-08-18

Publications (2)

Publication Number Publication Date
CN1323221A CN1323221A (zh) 2001-11-21
CN1263510C true CN1263510C (zh) 2006-07-12

Family

ID=26792625

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998121703A Expired - Fee Related CN1263510C (zh) 1998-08-19 1999-08-18 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用

Country Status (15)

Country Link
US (1) US20040213804A1 (enExample)
EP (1) EP1109576B1 (enExample)
JP (1) JP2004505885A (enExample)
KR (1) KR100704826B1 (enExample)
CN (1) CN1263510C (enExample)
AT (1) ATE446107T1 (enExample)
AU (1) AU771330B2 (enExample)
CA (1) CA2340692A1 (enExample)
CZ (1) CZ2001622A3 (enExample)
DE (1) DE69941574D1 (enExample)
HK (1) HK1041825B (enExample)
HU (1) HUP0103100A3 (enExample)
NO (1) NO20010805L (enExample)
NZ (1) NZ509986A (enExample)
WO (1) WO2000010599A2 (enExample)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
CN1441676B (zh) * 2000-03-31 2012-08-22 普渡研究基金会 用配体-免疫原缀合物治疗的方法
CA2413450C (en) * 2000-06-20 2014-02-18 Shire Biochem Inc. Streptococcus antigens
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
WO2004011027A1 (en) * 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
HUE031886T2 (en) 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2172213B1 (en) 2003-01-30 2013-04-03 Novartis AG Injectable vaccines against multiple meningococcal serogroups
CA2530364C (en) * 2003-06-23 2014-03-18 Baxter International Inc. Vaccines against group y neisseria meningitidis and meningococcal combinations thereof
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
NZ546430A (en) 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
US7422755B2 (en) * 2004-01-15 2008-09-09 The United States Of America As Represented By The Department Of Health And Human Services Antimultiorganism glycoconjugate vaccine
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
NZ550533A (en) 2004-04-30 2010-02-26 Novartis Vaccines & Diagnostic Meningococcal conjugate vaccination comprising N. meningitidis and diphtheria toxin
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
GB0502095D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
PE20110072A1 (es) 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
WO2007028408A1 (en) * 2005-09-05 2007-03-15 Glaxosmithkline Biologicals S.A. Serum bactericidal assay for n. meningitidis specific antisera
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
KR101515078B1 (ko) 2005-12-22 2015-04-24 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
EP1976857A4 (en) * 2006-01-13 2011-08-03 Baxter Int PROCESS FOR CLEANING POLYSACCHARIDES
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
PL2004225T3 (pl) 2006-03-22 2012-09-28 Novartis Ag Schematy immunizacji koniugatami meningokokowymi
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
JP5814507B2 (ja) 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
WO2008089403A2 (en) * 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
JP2010525035A (ja) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
CA2692069C (en) * 2007-06-20 2016-10-18 Baxter Healthcare S.A. Modified polysaccharides for conjugate vaccines
CA2690708A1 (en) 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN102356089B (zh) 2008-02-21 2014-02-19 诺华股份有限公司 脑膜炎球菌fHBP多肽
CA2777837C (en) 2008-10-27 2017-07-11 Novartis Ag Purification method
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
WO2010070453A2 (en) 2008-12-17 2010-06-24 Novartis Ag Meningococcal vaccines including hemoglobin receptor
EP3017826A1 (en) 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
EP2411048B1 (en) 2009-03-24 2020-05-06 GlaxoSmithKline Biologicals SA Adjuvanting meningococcal factor h binding protein
EP3263128A3 (en) 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Compositions for immunising against staphylococcus aureus
WO2010141312A2 (en) 2009-06-01 2010-12-09 Wake Forest University Health Sciences Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
BR112012009014B8 (pt) 2009-09-30 2022-10-04 Novartis Ag Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003924D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Immunogenic composition
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
CA2860331A1 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
CN102526724B (zh) * 2011-01-14 2015-07-22 四川大学 氢氧化铝凝胶-多糖复合免疫佐剂及其制备方法和用途
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
EP3269386B1 (en) 2011-12-06 2022-09-14 Valneva Austria GmbH Aluminium compounds for use in therapeutics and vaccines
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR101452830B1 (ko) * 2012-04-06 2014-10-21 아이진 주식회사 두 가지 항암물질을 동시에 제공하는 대장균 균주
RU2014151567A (ru) 2012-05-22 2016-07-10 Новартис Аг Конъюгат менингококка серогруппы х
JP6324961B2 (ja) 2012-09-06 2018-05-16 ノバルティス アーゲー 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン
TR201808684T4 (tr) 2012-10-02 2018-07-23 Glaxosmithkline Biologicals Sa Lineer olmayan sakarit konjügatları.
EP2906239A1 (en) 2012-10-12 2015-08-19 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
CN111249455A (zh) 2012-11-30 2020-06-09 葛兰素史密丝克莱恩生物有限公司 假单胞菌抗原和抗原组合
BR112015018014A2 (pt) 2013-02-01 2017-07-11 Glaxosmithkline Biologicals Sa liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll
DK2992098T3 (da) 2013-05-01 2019-06-17 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af hbv- og ttr-ekspression
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
KR20160127104A (ko) 2014-02-28 2016-11-02 글락소스미스클라인 바이오로지칼즈 에스.에이. 변형된 수막구균 fhbp 폴리펩티드
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017120524A1 (en) * 2016-01-07 2017-07-13 The Board Of Trustees Of The Leland Stanford Junior University Defined enzymatic synthesis of lipid a analogs
BR112019003992A2 (pt) 2016-09-02 2019-05-28 Sanofi Pasteur Inc vacina contra neisseria meningitidis
US12109259B2 (en) 2016-09-02 2024-10-08 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
BE1025162B9 (fr) 2016-12-06 2019-01-07 Glaxosmithkline Biologicals Sa Procede de purification pour les polysaccharides capsulaires
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3727437A4 (en) * 2017-12-19 2021-09-08 The Governors of the University of Alberta SURFACE GLYCANES OF CLOSTRIDIUM PERFRINGENS AND ASSOCIATED USES
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
EP3923982A1 (en) 2019-02-11 2021-12-22 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
JOP20200214A1 (ar) 2019-09-03 2021-03-03 Serum Institute Of India Pvt Ltd تركيبات مولدة للمناعة ضد الأمراض المعوية وطرق لتحضيرها
CN115003330A (zh) * 2019-09-23 2022-09-02 科纳克斯资本 作为疫苗和诊断工具的新糖缀合物
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3799884A1 (en) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions
CN119371566A (zh) 2020-02-21 2025-01-28 辉瑞公司 糖类的纯化
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
WO2022084852A1 (en) 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
PE20252774A1 (es) 2023-03-30 2025-12-22 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos
AU2024255922A1 (en) 2023-04-14 2025-10-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en) 2023-04-24 2024-10-31 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121569027A (zh) 2023-07-21 2026-02-24 葛兰素史克生物有限公司 免疫原性组合物
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
WO2025186705A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4459286A (en) * 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US5192540A (en) * 1988-04-19 1993-03-09 American Cyanamid Company Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
NL8802046A (nl) * 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
HU9201966D0 (en) * 1989-12-14 1992-10-28 Ca Nat Research Council An improved vaccine of meningococcus-polysaccharide conjunction
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US5554730A (en) * 1993-03-09 1996-09-10 Middlesex Sciences, Inc. Method and kit for making a polysaccharide-protein conjugate
US5439808A (en) * 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines

Also Published As

Publication number Publication date
AU5780099A (en) 2000-03-14
WO2000010599A3 (en) 2000-06-22
CZ2001622A3 (cs) 2002-01-16
HUP0103100A2 (hu) 2001-11-28
DE69941574D1 (de) 2009-12-03
NZ509986A (en) 2003-10-31
NO20010805L (no) 2001-04-03
NO20010805D0 (no) 2001-02-16
HK1041825B (zh) 2007-02-23
AU771330B2 (en) 2004-03-18
EP1109576A2 (en) 2001-06-27
KR100704826B1 (ko) 2007-04-09
KR20010072776A (ko) 2001-07-31
JP2004505885A (ja) 2004-02-26
EP1109576B1 (en) 2009-10-21
HUP0103100A3 (en) 2005-11-28
ATE446107T1 (de) 2009-11-15
CN1323221A (zh) 2001-11-21
WO2000010599A8 (en) 2000-08-10
US20040213804A1 (en) 2004-10-28
CA2340692A1 (en) 2000-03-02
HK1041825A1 (en) 2002-07-26
WO2000010599A2 (en) 2000-03-02

Similar Documents

Publication Publication Date Title
CN1263510C (zh) 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用
JP7851988B2 (ja) 非天然アミノ酸とのポリペプチド抗原接合体
KR910002553B1 (ko) 폴리삭카라이드-단백질 결합체 및 이의 제조방법
JP5144613B2 (ja) ワクチンとしてまたは結合体ワクチンとしてタンパク質に連結して使用するための細菌莢膜多糖の抽出および単離法
JP5286089B2 (ja) ポリサッカライドを精製する方法
US7157443B2 (en) Staphylococcus aureus exopolysaccharide and process
CA2223080C (en) Antigenic group b streptococcus type ii and type iii polysaccharide fragments having a 2,5-anhydro-d-mannose terminal structure and conjugate vaccine thereof
JP2008523142A (ja) ペプチドグリカンを含有する複合糖質ワクチン
WO2020010016A1 (en) Self-adjuvanted immunogenic conjugates
RU2249463C2 (ru) Иммуногенный конъюгат бета-пропионамид-связанного полисахарида с белком, использующийся в качестве вакцины
US20010051364A1 (en) Procedures for the extraction and isolation of bacterial capsular polysaccharides for use as vaccines or linked to proteins as conjugate vaccines
US9616139B2 (en) Conjugating amines
Oldrini Well-defined glycoconjugates via chemo-enzymatic synthesis of oligosaccharides
EA044044B1 (ru) Иммуногенные композиции, содержащие конъюгаты полипептид-антиген с неприродными аминокислотами

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060712

Termination date: 20100818